RE: 50p19 Feb 2024 09:09
I get the information from the trading update, I assume it will be released soon from this
During FY23, Eroxon received regulatory approval in our key target markets, including FDA approval in the US, the largest market for ED in the world. Following this, the Company was delighted to announce that it had entered into an agreement with Haleon plc, the world leading consumer healthcare company, for exclusive marketing & distribution rights in the US. Futura continues to work with Haleon on preparation for the US launch and looks forward to updating shareholders in due course.
My interpretation